Core Insights - Perspective Therapeutics, Inc. is set to report its third quarter 2025 financial results and provide a business update on November 10, 2025, after market close [1] Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, focusing on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2] - The company is also developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Clinical Programs - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]

Group 1 - The conference is focused on the updated interim clinical data for VMT-alpha-NET being presented at the European Society of Medical Oncology Congress 2025 (ESMO) [2] - The call includes forward-looking statements that are subject to risks and uncertainties, with details available in the company's SEC filings [2][3]

Summary of Perspective Therapeutics Conference Call Company Overview - **Company**: Perspective Therapeutics (NYSEAM:CATX) - **Event**: Update on VMT AlphaNet clinical data presented at the European Society of Medical Oncology (ESMO) Congress 2025 Key Industry Insights - **Focus**: Development of next-generation targeted therapies for neuroendocrine tumors (NETs) - **Clinical Pipeline**: Active clinical and preclinical pipelines with multiple readouts expected through mid-2026 and beyond [6][39] Core Data and Findings - **VMT AlphaNet Program**: - Completed recruitment for the second dose cohort at 5 millicuries and the DLT cohort at 6 millicuries [7] - Melanoma program enrolling at 3 millicuries in both monotherapy and combination therapies [7] - FAP program now enrolling at 5 millicuries, escalated from 2.5 millicuries [7] - **Interim Data**: - Encouraging interim readout with an overall response (OR) rate of 44% and a median follow-up of 41 weeks for patients intended for registrational trials [8][15] - Patients continue to achieve late objective responses as the trial progresses, which is typical for this tumor type [10] - **Safety Profile**: - Treatment-emergent adverse events are mostly mild, with common events being fatigue and alopecia [22] - No dose-limiting toxicities or serious renal complications reported [34] - Creatinine levels remained stable, with only mild increases observed in a few patients [24] Important Considerations - **Patient Selection**: - Focus on "LUTIVAIR naive" patients who have not received prior radiopharmaceutical therapy [12] - Two analyses planned: one for all patients with at least one tumor expressing SSTR2 and another for patients where all tumors express SSTR2 [13] - **Comparative Analysis**: - The response rate of 44% is higher than the published data with Lutathera from the NETTER-one trial [34] - The study design allows for a broader patient eligibility, which may affect the response rates [56] - **Future Directions**: - Plans to accelerate towards pivotal studies based on clinical interest and demand [72] - Continuous follow-up and data collection to refine understanding of response kinetics and safety [39][60] Additional Insights - **Response Kinetics**: - Delayed responses are common in slower proliferating tumors, with some patients showing significant tumor shrinkage after extended treatment periods [61][110] - The importance of long-term follow-up to assess gradual tumor responses [31] - **Differentiation from Competitors**: - Perspective Therapeutics' product shows a favorable safety profile compared to competitors, with no reports of dysphagia, which is a significant concern with other treatments [80][81] - **Clinical Relevance**: - The data presented indicates a potentially meaningful tool for clinicians treating patients with neuroendocrine tumors, emphasizing the importance of quality of life and safety in long-term treatment [118] This summary encapsulates the key points from the conference call, highlighting the company's focus on innovative therapies, promising clinical data, and the importance of patient safety and response evaluation in the treatment of neuroendocrine tumors.

Legal Disclaimers Investor Call ESMO 2025 Presentation October 20, 2025 NYSE AMERICAN: CATX Forward-looking statements contained in this presentation are made as of this date. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward- looking statements whether as a result of new information, future events or otherwise. Innovative Platform Technology Robust Manufacturing Infrastructure This presentation contains forward-looking statements within the meani ...

[Filing Information](index=1&type=section&id=Filing%20Information) Details registrant identification, principal offices, and registered securities for Perspective Therapeutics, Inc [Registrant Information](index=1&type=section&id=Registrant%20Information) Provides core identification details for Perspective Therapeutics, Inc., including incorporation, principal executive offices, and registered securities - **Registrant**: Perspective Therapeutics, Inc., incorporated in Delaware[2](index=2&type=chunk) - Principal Executive Offices: 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121, Telephone: (206) 676-0900[2](index=2&type=chunk) Registered Securities | Title of each class | Symbol(s) | Name of each exchange on which registered | | :------------------ | :-------- | :---------------------------------------- | | Common Stock, $0.001 par value | CATX | NYSE American LLC | [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Perspective Therapeutics, Inc. announced updated interim clinical trial results and preliminary estimated financial information as of September 30, 2025, noting these figures are unaudited and subject to change - On October 20, 2025, the Company announced updated interim results from its Phase 1/2a clinical trial of **[212Pb]VMT-α-NET** for neuroendocrine tumors[6](index=6&type=chunk) - The Press Release and Presentation include estimated **cash, cash equivalents, and short-term investments** as of September 30, 2025[6](index=6&type=chunk) - All estimated and projected financial information is **preliminary, unaudited**, and not reviewed by the independent registered public accounting firm[6](index=6&type=chunk)[7](index=7&type=chunk) [Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%208.01%20Other%20Events%20and%20Item%209.01%20Financial%20Statements%20and%20Exhibits) Details the filing of a Press Release and Presentation as exhibits to the 8-K report, providing further clinical and business updates - On October 20, 2025, the Company issued a Press Release and Presentation, both filed as exhibits to this 8-K report[8](index=8&type=chunk) Filed Exhibits | Exhibit No. | Description | | :------------ | :-------------------------------------------------- | | 99.1 | Press Release dated October 20, 2025 | | 99.2 | Presentation | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Signatures](index=4&type=section&id=SIGNATURES) The report was officially signed on October 20, 2025, by Johan (Thijs) Spoor, CEO of Perspective Therapeutics, Inc., affirming compliance - The report was signed by **Johan (Thijs) Spoor**, Chief Executive Officer of Perspective Therapeutics, Inc., on October 20, 2025[14](index=14&type=chunk)

Core Insights - Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors (NETs) at the ESMO Congress 2025 [1][2] Clinical Trial Results - The interim results were based on a data cut-off date of September 12, 2025, involving 55 patients across three dose cohorts who received at least one treatment of VMT-α-NET [2] - The objective response rate was reported at 44% (7 of 16 patients) in Cohort 2, with a median follow-up of 41 weeks, and 14 out of 16 patients remained free from progression [5][6] - Safety findings indicated no dose-limiting toxicities, no treatment-related discontinuations, and no serious renal complications among the patients [6] Expert Commentary - Richard Wahl, a professor at Washington University, highlighted the durable anti-tumor activity and excellent tolerability of [Pb]VMT-α-NET, emphasizing its potential as a treatment option for progressive NETs [4] - Markus Puhlmann, Chief Medical Officer, noted the compelling clinical profile of VMT-α-NET at the 5 mCi dose and the importance of the study for future registration [4] Future Developments - Initial efficacy data for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3 are expected to be presented in 2026 [5][9] - The company is exploring whether a higher dose or refined patient selection criteria could enhance VMT-α-NET's clinical profile [7] Financial Position - As of September 30, 2025, the company's cash, cash equivalents, and short-term investments were approximately $174.1 million, expected to fund operations into late 2026 [8]

Core Viewpoint - Perspective Therapeutics, Inc. has initiated the treatment of the first patient in the second cohort of its Phase 1/2a trial for the radiopharmaceutical [Pb]PSV359, targeting solid tumors expressing fibroblast activation protein alpha (FAP-α) [1][3] Group 1: Clinical Trial Details - The second cohort of the trial involves patients receiving [Pb]PSV359 at a dose of 5.0 mCi for up to four doses every eight weeks, with a recommendation from the Safety Monitoring Committee to evaluate higher doses based on initial patient responses [2][5] - The primary objective of the trial is to assess the safety and tolerability of various doses of [Pb]PSV359, aiming to determine the recommended Phase 2 dose for further study [5] Group 2: Mechanism and Targeting - [Pb]PSV359 is designed to target tumor sites expressing FAP-α, which is associated with several prevalent solid tumors, providing a potential treatment option for patients with limited alternatives [4][6] - FAP-α is predominantly expressed on cancer-associated fibroblasts in the tumor microenvironment and is linked to poor prognosis in various solid tumors, including pancreatic and colorectal cancers [6] Group 3: Company Overview - Perspective Therapeutics, Inc. specializes in developing radiopharmaceuticals that utilize alpha-emitting isotopes to deliver targeted radiation to cancer cells, enhancing treatment efficacy while minimizing toxicity [7] - The company is also advancing complementary imaging diagnostics that utilize the same targeting moieties, facilitating personalized treatment approaches [7][8]

Core Insights - Perspective Therapeutics has initiated a new cohort in a Phase 1/2a trial for [Pb]VMT01, a targeted alpha-particle therapy, in combination with nivolumab for patients with metastatic melanoma [1][2][3] - The trial aims to evaluate the safety and efficacy of [Pb]VMT01, with a focus on its potential to transform treatment for difficult-to-treat cancers [3][4] Company Overview - Perspective Therapeutics is a radiopharmaceutical company focused on developing advanced cancer treatments using alpha-emitting isotopes [6][7] - The company has proprietary technology that targets cancer cells specifically, aiming to improve treatment efficacy while minimizing toxicity [6][7] Product Development - The [Pb]VMT01 therapy targets tumors expressing the melanocortin 1 receptor (MC1R), which is often overexpressed in metastatic melanoma [4] - The FDA granted Fast Track Designation for [Pb]VMT01, expediting its development for patients with unresectable or metastatic melanoma [4] Clinical Trial Details - The new cohort will administer [Pb]VMT01 at a dose of 3.0 mCi in combination with nivolumab, following positive early safety and anti-tumor activity results from previous dosing [2][3] - The Safety Monitoring Committee has recommended evaluating higher doses based on initial patient responses [2] Market Context - Melanoma is a significant health concern, with approximately 100,000 new diagnoses and 8,300 deaths annually in the U.S. [5] - Metastatic melanoma has a poor prognosis, with limited survival rates, highlighting the need for new treatment options [5]

Core Insights - Perspective Therapeutics, Inc. has appointed Joel Sendek as the new Chief Financial Officer, effective immediately, bringing extensive experience in biotech finance and equity research [1][2][3] - Sendek has a proven track record, having raised over $2.5 billion in corporate finance transactions and recognized as an All-Star Analyst by The Wall Street Journal [2] - The company is advancing its clinical programs in the targeted alpha radiopharmaceutical field, with ongoing trials for neuroendocrine tumors, melanoma, and solid tumors [3][5] Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb for targeted radiation delivery [4] - The company is also working on complementary imaging diagnostics to personalize treatment and optimize patient outcomes through a "theranostic" approach [4] Clinical Programs - The company's clinical programs include VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, all currently in Phase 1/2a trials in the U.S. [5] - Perspective is expanding its regional network of drug product candidate finishing facilities to support clinical trials and commercial operations [5]

Core Insights - Perspective Therapeutics, Inc. has appointed Maya Martinez-Davis as an independent director to its Board of Directors, effective immediately [1][3] - Ms. Martinez-Davis brings extensive experience in the pharmaceutical industry, having held leadership roles at GSK, Merck KGaA, and Pfizer, particularly in oncology and specialty products [2][3] - The company is focused on pioneering advanced radiopharmaceutical treatments for cancer, utilizing proprietary technology that employs alpha-emitting isotopes for targeted therapy [4][5] Company Overview - Perspective Therapeutics specializes in radiopharmaceuticals aimed at treating various cancers, leveraging alpha-emitting isotopes to deliver radiation directly to cancer cells [4] - The company is developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes through a "theranostic" approach [4] - Current clinical-stage programs include treatments for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01), and solid tumors (PSV359), which are in Phase 1/2a trials in the U.S. [5] Leadership and Strategic Direction - Lori Woods, Chairperson of Perspective, expressed enthusiasm about Ms. Martinez-Davis joining the board, highlighting her complementary experience to existing directors and management [3] - Ms. Martinez-Davis aims to contribute insights to advance the company's clinical programs and enhance shareholder value [3] - CEO Thijs Spoor emphasized the potential of the company's innovative science to develop new medicines that could significantly improve patient lives [3]